На этой странице перечислены больницы направления «Трансплантация печени и гепатобилиарная хирургия» (включая Intestine Transplant) в Ченнаи, Индия, включая Apollo Hospitals, Greams Road, Gleneagles Global Hospital, Dr. Rela Institute and Medical Centre, SIMS Hospital и другие.
Спросите нас о «Intestine Transplant» в Ченнаи, Индия
Оставьте свои данные — наша команда координации свяжется с вами и расскажет о следующих шагах.
Сравните 8 аккредитованных больниц (Трансплантация печени и гепатобилиарная хирургия) в Ченнаи, Индия
Рекомендуем🇮🇳 Apollo Hospitals, Greams Road
Больница занимает 1-е место в этом списке по указанному рейтингу (4.7/5, 125 отзывов).
🇮🇳 Gleneagles Global Hospital
Больница занимает 2-е место в этом списке по указанному рейтингу (4.7/5, 112 отзывов).
🇮🇳 Dr. Rela Institute and Medical Centre
Больница занимает 3-е место в этом списке по указанному рейтингу (4.7/5, 108 отзывов).
🇮🇳 SIMS Hospital
Больница занимает 4-е место в этом списке по указанному рейтингу (4.6/5, 20 отзывов).
🇮🇳 Sankara Nethralaya
Больница занимает 5-е место в этом списке по указанному рейтингу (4.4/5, 220 отзывов).
🇮🇳 Apollo First Med Hospitals, Kilpauk
Больница занимает 6-е место в этом списке по указанному рейтингу (4.4/5, 76 отзывов).
🇮🇳 MIOT International
Больница занимает 7-е место в этом списке по указанному рейтингу (4.4/5, 200 отзывов).
🇮🇳 MGM Healthcare
Больница занимает 8-е место в этом списке по указанному рейтингу (3.7/5, 34 отзывов).
Как мы выбираем эти больницы
Больница появляется на этой странице, если направление «Трансплантация печени и гепатобилиарная хирургия» указано среди её специализаций и она находится в Ченнаи, Индия. Сортировка — по указанному рейтингу (по убыванию), без редакционного рейтинга «лучших».
Как выбрать лучшую больницу для «intestine transplant» в Ченнаи, Индия?
Выбор подходящей больницы для «intestine transplant» — важное решение в вашем пути лечения. Вот на что стоит обратить внимание:
Международная аккредитация
Ищите больницу с международной аккредитацией, например JCI или NABH — см. отметки аккредитации у каждой больницы ниже.
Специализация
Убедитесь, что в больнице есть отделение, специализирующееся на «Трансплантация печени и гепатобилиарная хирургия», а не только общая помощь.
Мощность и опыт
Количество коек и год основания, указанные ниже, отражают масштаб и операционный опыт больницы.
Прозрачность стоимости
Запросите детализированную смету перед поездкой — используйте наш калькулятор стоимости для первичной оценки.
Что нужно знать о процедуре «Intestine Transplant»
Intestinal transplantation — encompassing isolated small bowel, liver-intestine combined, and full multi-visceral procedures — is one of the most technically demanding solid-organ transplants in modern surgery, offering a life-saving solution for patients with irreversible intestinal failure and total parenteral nutrition (TPN) dependence. Leading transplant centres in India and the UAE report one-year graft survival rates exceeding 80–85% for isolated intestinal transplants when performed at high-volume programmes, with five-year patient survival approaching 60–65% as immunosuppression protocols have matured. GAF Healthcare connects international patients with JCI- and NABH-accredited hospitals in India and JCI- and DHA-licensed centres in Dubai and Abu Dhabi, providing end-to-end clinical coordination, transparent pricing, and dedicated patient navigation from initial evaluation through long-term post-transplant follow-up. Hospital Stay: 45–90 days (ICU phase 10–21 days, followed by step-down ward care; duration depends on graft type — isolated intestine vs. multi-visceral — and post-operative course) • Total Stay in Country (Fit-to-Fly): 12–20 weeks (international air travel is generally cleared only after sustained enteral tolerance, stable tacrolimus trough levels, absence of acute rejection episodes, and infectious clearance; most programmes require a minimum 90-day in-country observation period before considering repatriation) • Success Rate: 80–85% one-year graft survival (isolated intestinal transplant); 70–78% one-year graft survival (multi-visceral transplant) at accredited high-volume centres
Clinical Overview
Intestinal failure is defined as the reduction of functional gut mass below the minimum necessary for adequate digestion and absorption of macronutrients, micronutrients, water, and electrolytes to sustain life without intravenous supplementation. The commonest causes requiring transplant evaluation include short bowel syndrome secondary to massive resection (Crohn's disease, mesenteric vascular catastrophe, radiation enteritis, volvulus, or necrotising enterocolitis in neonates), chronic intestinal pseudo-obstruction, and extensive mucosal disorders such as microvillus inclusion disease or tufting enteropathy. Patients with fewer than 100 cm of residual small bowel in adults — or less than 20–25 cm without an intact colon — almost universally require long-term TPN, which carries a compounding risk of TPN-associated liver disease (TPNALD), central venous catheter-related bloodstream infections (CRBSIs), venous thrombosis, and metabolic bone disease. Once hepatic fibrosis or cirrhosis supervenes from TPNALD, a combined liver-intestine or full multi-visceral graft becomes necessary, substantially increasing operative complexity. The anatomical and immunological demands of intestinal transplantation are unique among solid-organ procedures. The small bowel allograft carries the largest burden of donor lymphoid tissue of any transplanted organ — including Peyer's patches, mesenteric lymph nodes, and lamina propria lymphocytes — making it the most immunogenic organ transplanted in clinical practice. This drives a high baseline rate of acute cellular rejection (ACR), which must be distinguished histologically from graft-versus-host disease (GVHD), infection (particularly cytomegalovirus enteritis and Epstein-Barr virus-associated post-transplant lymphoproliferative disorder, EBV-PTLD), and non-specific ileitis. Surveillance endoscopy with protocol biopsies — typically performed twice weekly in the first month, then weekly through month three — is therefore a mandatory and resource-intensive component of post-transplant care, requiring centres with dedicated transplant gastroenterologists and pathologists experienced in intestinal graft pathology. Standard of care in 2024 is guided by the International Intestinal Transplant Registry (ITR) and protocols from pioneer programmes (Pittsburgh, Miami, Birmingham). Current immunosuppression backbone universally includes tacrolimus (target troughs 10–15 ng/mL early, titrated to 8–12 ng/mL by six months), with induction using either rabbit anti-thymocyte globulin (rATG) or the IL-2 receptor antagonist basiliximab, supplemented by corticosteroid tapering. Sirolimus (mTOR inhibitor) may be added for its anti-proliferative effect in cases of EBV-PTLD risk. Prophylaxis regimens include trimethoprim-sulfamethoxazole (Pneumocystis), ganciclovir or valganciclovir (CMV, particularly in D+/R− mismatches), and fluconazole or micafungin (fungal). Nutritional rehabilitation — the transition from TPN to enteral and ultimately oral feeding — is the primary functional outcome measure and is supervised by transplant dietitians using ileostomy output monitoring, faecal calprotectin, and citrulline plasma levels as non-invasive markers of enterocyte mass and graft function.
Who is a Candidate?
• ELIGIBLE DIAGNOSES (INDICATIONS): • Irreversible intestinal failure with dependence on total parenteral nutrition (TPN) for >12 months • Short bowel syndrome with residual small bowel <100 cm (adult) or <20–25 cm (neonate/infant) without intact colon • Crohn's disease with extensive small bowel resection and TPN-associated complications • Mesenteric vascular occlusion (superior mesenteric artery thrombosis or embolism) with massive gut infarction • Radiation enteritis with pan-intestinal dysfunction • Chronic intestinal pseudo-obstruction (CIPO) refractory to prokinetics and surgical interventions • Microvillus inclusion disease (MVID) and tufting enteropathy in paediatric patients • Abdominal desmoid tumour involving the mesenteric root precluding conventional resection • Familial adenomatous polyposis (FAP) with extensive mesenteric desmoid disease • Functional short gut in patients who have lost all central venous access sites (catheter salvage failure) • Recurrent life-threatening catheter-related bloodstream infections (≥2 per year with systemic sepsis) • TPN-associated liver disease (TPNALD) progressing to fibrosis/cirrhosis → indication for combined liver-intestine or multi-visceral transplant • GRAFT TYPE SELECTION CRITERIA: • Isolated intestinal transplant: intestinal failure WITHOUT significant liver disease (bilirubin <3 mg/dL, no portal hypertension, no fibrosis on biopsy) • Combined liver-intestine transplant: intestinal failure WITH established TPNALD (biopsy-proven fibrosis/cirrhosis, bilirubin >3–5 mg/dL, portal hypertension) • Full multi-visceral transplant (stomach + duodenum + pancreas + intestine ± liver): gastric dysmotility, extensive mesenteric thrombosis involving portomesenteric venous system, or portal vein thrombosis precluding standard vascular reconstruction; also Gardner syndrome/desmoid tumours requiring en-bloc resection • Modified multi-visceral (without liver): portal hypertension with preserved hepatic function but complex mesenteric vascular anatomy • REQUIRED PRE-TRANSPLANT DIAGNOSTIC WORKUP: • Contrast-enhanced CT angiography of abdomen/pelvis (mesenteric vascular anatomy, portal vein patency, residual bowel mapping) • MRI enterography (mucosal disease assessment, fistula mapping in Crohn's) • Liver biopsy (staging of TPNALD — Ishak or METAVIR scoring) • Transthoracic echocardiography (ECHO) with Doppler (cardiac function, pulmonary hypertension screen — PA systolic pressure >35 mmHg is a relative contraindication) • Pulmonary function tests (FEV1, DLCO — respiratory reserve assessment) • Bone density scan (DEXA) — TPN patients frequently have severe osteopaenia • Serological panel: CMV IgG, EBV IgG, HSV, VZV, HIV, HBsAg, HBcAb, HCV RNA, HTLV-I/II, RPR/TPHA (syphilis), Toxoplasma IgG • HLA typing (Class I and II) and Panel Reactive Antibody (PRA) / donor-specific antibody (DSA) screening — critical for crossmatch strategy • Blood group and extended red cell antigen typing • Full metabolic panel: liver function, kidney function (eGFR — tacrolimus nephrotoxicity risk stratification), coagulation (PT, INR, factor V level) • Nutritional biochemistry: 25-OH Vitamin D, zinc, selenium, magnesium, phosphorus, thiamine, folate, B12 • Psychiatric evaluation and social work assessment (medication adherence potential, caregiver support structure — mandatory component) • Age-appropriate cancer screening: colonoscopy, mammography, PAP smear, PSA, low-dose CT chest • ABSOLUTE CONTRAINDICATIONS: • Uncontrolled systemic sepsis or multi-drug-resistant organism (MDRO) colonisation that cannot be cleared • Active or recent (within 5 years) extra-hepatic malignancy without documented complete remission • Severe irreversible cardiopulmonary dysfunction (LVEF <30%, mean PAP >35 mmHg on right heart catheterisation) • Uncontrolled autoimmune disease with high-dose immunosuppression requirements that would be compounded • Active alcohol or substance dependence without documented rehabilitation • Demonstrated and persistent non-compliance with prior medical regimens (psychiatric evaluation mandatory) • Significant neurological impairment precluding understanding of post-transplant care demands • RELATIVE CONTRAINDICATIONS (case-by-case multidisciplinary review): • Morbid obesity (BMI >35 kg/m² — operative and wound healing risk) • Advanced chronic kidney disease (eGFR <30 mL/min — calcineurin inhibitor nephrotoxicity will accelerate progression) • Prior extensive abdominal surgeries with hostile abdomen (mesh, dense adhesions — surgical feasibility assessment required) • High PRA (>50%) or pre-formed donor-specific antibodies (require desensitisation protocols) • CMV D+/R− mismatch (manageable with extended prophylaxis but increases risk of severe CMV disease)
Treatment Options & Approaches
GRAFT TYPES AND SURGICAL TECHNIQUES: 1. ISOLATED INTESTINAL TRANSPLANT (IIT): The allograft consists of the donor jejunum and ileum, typically 150–200 cm, preserving the ileocaecal valve where possible to enhance absorption and reduce bacterial translocation. Vascular reconstruction is achieved by end-to-side anastomosis of the donor superior mesenteric artery (SMA) to the recipient infrarenal aorta, and the donor portal/superior mesenteric vein (SMV) to the recipient SMV or infrarenal inferior vena cava (IVC). The proximal bowel is anastomosed in a Roux-en-Y or straight end-to-end/side-to-side configuration depending on recipient anatomy. A distal loop ileostomy (Bishop-Koop or standard end ileostomy) is created to allow direct endoscopic surveillance of the allograft mucosa — this is a defining feature of intestinal transplant management. Stoma reversal is typically planned at 6–12 months post-transplant in stable patients. 2. COMBINED LIVER-INTESTINE TRANSPLANT: The liver and small bowel are transplanted as a composite allograft sharing the hepatic vessels and portal venous system. The donor coeliac axis and SMA are often retained on a Carrel patch. This is technically preferred over sequential transplantation when TPNALD has caused portal hypertension, as the shared venous drainage eliminates the need for complex venous reconstruction. The liver graft confers partial immunological protection to the intestinal allograft (the 'immunological umbrella' effect), permitting marginally lower tacrolimus targets and potentially reducing rejection burden. 3. FULL MULTI-VISCERAL TRANSPLANT (MVTx): En-bloc procurement and implantation of the stomach, duodenum, head of pancreas, small bowel, and liver (and occasionally colon). This is the most physiologically complete reconstruction and is required when the native upper gastrointestinal tract is non-functional (as in diffuse mesenteric thrombosis or pan-alimentary dysmotility). Arterial inflow is via a bifurcated donor aortic conduit encompassing both the coeliac and superior mesenteric axes. Venous outflow is through the donor IVC (piggyback or classical technique). Total operative time typically ranges 10–18 hours with a multidisciplinary team including transplant surgeons, hepatobiliary surgeons, vascular surgeons, and anaesthesiologists expert in massive transfusion protocols. 4. MODIFIED MULTI-VISCERAL TRANSPLANT (without liver): For patients requiring stomach and pancreatoduodenal replacement but with preserved hepatic function and non-cirrhotic portal hypertension. Preserves the native liver, reducing cholestatic complications and bile duct reconstruction complexity. 5. DONOR SELECTION AND ORGAN PROCUREMENT: • Deceased donor (cadaveric, brain-dead or, increasingly, donation after circulatory death — DCD) is the standard source. • Living donor intestinal transplant (LDIT): highly specialised, involving 150–200 cm segmental small bowel donation from an ABO-compatible related donor. Only a handful of centres worldwide perform this routinely. Not yet widely available in India or the UAE but under development at select academic centres. • Cold ischaemia time is critically limited to <8–10 hours for intestinal grafts (compared with 24 hours for kidneys), placing extreme logistical demands on procurement and implantation teams. • Machine perfusion (normothermic or hypothermic): emerging technology for intestinal graft preservation. Normothermic machine perfusion (NMP) with oxygenated perfusate allows ex-vivo viability assessment (bile production for liver component, peristaltic activity, mucosal integrity fluorescence) before implantation. Available at select centres in India's metro transplant hubs. 6. IMMUNOSUPPRESSION PROTOCOLS (DRUG CLASSES AND TARGETS): • Induction: rATG (rabbit anti-thymocyte globulin, 1.5 mg/kg/day for 3–5 days) OR basiliximab (IL-2R antagonist, 20 mg on days 0 and 4) — centre-dependent • Maintenance backbone: Tacrolimus (calcineurin inhibitor) — trough targeting 12–15 ng/mL months 1–3, reducing to 8–12 ng/mL thereafter • Adjunct maintenance: Mycophenolate mofetil (MMF) 500–1000 mg twice daily; role is more limited than in kidney transplant due to mucosal side effects • mTOR inhibitors (sirolimus, everolimus): used selectively in EBV+ / PTLD-risk patients or as calcineurin-sparing agents for nephrotoxicity • Corticosteroids: pulsed methylprednisolone (500–1000 mg IV) for ACR treatment; rapid taper targeting steroid-free maintenance by 6–12 months in stable patients • Novel and investigational agents: Belatacept (CTLA4-Ig co-stimulation blockade), Vedolizumab (gut-selective anti-integrin — investigational for chronic rejection), donor-specific regulatory T-cell therapy (Treg infusions — in clinical trials at ITR centres) 7. REJECTION SURVEILLANCE TECHNOLOGY: • Wireless capsule endoscopy: used in centres with stoma reversal to monitor distal allograft mucosa non-invasively • Citrulline plasma levels: functional biomarker of enterocyte mass; levels <20 µmol/L correlate with significant rejection or villous atrophy • Donor-derived cell-free DNA (dd-cfDNA): emerging liquid biopsy marker for early rejection detection, now validated in intestinal transplant (analogous to AlloSure in kidney transplant) • Confocal laser endomicroscopy: allows real-time in-vivo histology at the time of surveillance endoscopy 8. NUTRITIONAL REHABILITATION STRATEGY: • Phase 1 (immediate post-transplant): TPN continued; enteral feeding initiated via nasojejunal or jejunostomy tube within 24–72 hours at trophic rates (10–20 mL/hour elemental formula) • Phase 2 (weeks 2–6): Gradual advancement of enteral feeds correlated with ileostomy output (<1200 mL/day target); TPN weaned in parallel • Phase 3 (months 1–6): Introduction of oral diet (low-oxalate, low-fat, high-complex carbohydrate); loperamide and oral rehydration solutions to control output • Phase 4 (months 6–12): TPN independence — the primary functional outcome; achieved in approximately 75–80% of survivors at one year • Gut rehabilitation pharmacotherapy: Teduglutide (GLP-2 analogue) may be used in the pre-transplant period to maximise residual bowel adaptation and potentially avoid or delay transplantation
Восстановление
PHASE 1 — INTERNATIONAL PATIENT EVALUATION (Weeks 1–4 before transplant listing): • GAF Healthcare coordinates submission of complete medical records (operative reports, TPN prescription, liver biopsy, imaging, serology) to the selected transplant centre for remote triage review by the transplant hepatologist and surgeon • Virtual MDT (multidisciplinary team) consultation conducted via video conferencing — patient and family receive a preliminary transplant suitability assessment and graft type recommendation • Travel to India or UAE for in-person evaluation: 3–5 days of outpatient investigations including CT angiography, ECHO, PFTs, crossmatch serology, HLA typing, and psychiatric/social work assessment • Formal MDT listing decision communicated within 5–7 business days of completed workup • Patient registered on the national waiting list (NOTTO — National Organ and Tissue Transplant Organisation — in India; Dubai Health Authority organ procurement registry in UAE) • Waiting period: variable (weeks to months depending on donor availability, blood group, and body size matching); paediatric patients often have shorter waits due to paediatric donor priority schemes PHASE 2 — PRE-TRANSPLANT OPTIMISATION (Waiting period): • Patient and one adult family caregiver required to reside within 2–4 hours of the transplant centre (GAF Healthcare arranges serviced medical accommodation) • Continuation of TPN via existing central venous access; regular outpatient monitoring (weekly LFTs, tacrolimus levels if pre-sensitised, nutritional biochemistry) • Infection clearance: any active CRBSI treated and line changed before activation on waiting list • Optimisation of bone density (IV bisphosphonate if severe osteopaenia), cardiac function, and nutritional status • Patient and caregiver education sessions: stoma care, medication administration, rejection symptom recognition, food safety protocols • 24/7 on-call availability required — transplant call can occur at any hour with typically 4–6 hours notice from organ offer to operative start PHASE 3 — TRANSPLANT SURGERY DAY: • Organ offer received; crossmatch performed urgently (flow cytometry crossmatch, typically 2–4 hours) • Patient admitted and undergoes final pre-operative assessment: blood count, coagulation, electrolytes, ECG, anaesthesia review • Induction immunosuppression administered (rATG Day 0) • Operative duration: 6–10 hours (isolated intestinal transplant); 10–18 hours (multi-visceral transplant) • Intraoperative monitoring: arterial line, central venous catheter, pulmonary artery catheter or transoesophageal echocardiography (TOE) for haemodynamic guidance; cell salvage (autotransfusion) used where oncologically safe • Immediate post-operative transfer to transplant-dedicated ICU or multi-organ transplant unit PHASE 4 — ICU AND EARLY POST-OPERATIVE PERIOD (Days 1–21): • Days 1–3: Mechanical ventilation, haemodynamic stabilisation, fluid balance optimisation, vasopressor weaning; tacrolimus initiated enterally or IV once haemodynamically stable • Days 3–5: Extubation if respiratory parameters adequate; first surveillance endoscopy via ileostomy (visual assessment of mucosal perfusion, colour, peristalsis) • Days 5–7: Trophic enteral feeds initiated via jejunostomy; TPN continued in parallel; first protocol biopsy • Days 7–14: Surveillance endoscopy + biopsy twice weekly; tacrolimus trough monitoring daily; CMV PCR and EBV PCR twice weekly; gradual advancement of enteral feeds if biopsy clear • Day 14–21: Transition from ICU to transplant step-down ward if: haemodynamically stable, no acute rejection on biopsy, tolerating enteral feeds at 30–50% of caloric target, wound healing satisfactory PHASE 5 — WARD REHABILITATION (Days 21–60): • Weekly then biweekly surveillance endoscopy with biopsy; pathology reviewed by transplant pathologist using Ruiz grading scale (Grade 0 — no rejection; Grade 1 — mild indeterminate; Grade 2 — mild ACR; Grade 3 — moderate ACR; Grade 4 — severe ACR) • Gradual advance of oral diet under transplant dietitian supervision; tracking ileostomy output daily • Physical and occupational therapy initiated: progressive mobilisation, reconditioning from prolonged pre-transplant debility • Medication reconciliation and patient education: patient must self-administer tacrolimus, mycophenolate, prophylactic antimicrobials, and monitor own vital signs by discharge • Target TPN independence (partial or full) before discharge PHASE 6 — PRE-DISCHARGE AND FIT-TO-FLY ASSESSMENT (Weeks 12–20): • International patients cleared for repatriation only when ALL of the following criteria are met: a) Minimum 90 days post-transplant b) No acute rejection episode in preceding 4 weeks (biopsy-confirmed) c) Stable tacrolimus troughs within therapeutic range for ≥4 consecutive weeks d) CMV and EBV PCR undetectable for ≥4 weeks e) Tolerating ≥75% of caloric requirements enterally or orally (significant TPN reduction or full independence) f) Patient and caregiver independently competent in all self-care tasks g) Receiving transplant programme in home country identified and care plan transmitted • GAF Healthcare coordinates medical escort (transplant nurse or physician) for long-haul repatriation flights where clinically indicated • Comprehensive discharge package: full medication list, drug levels, biopsy reports, immunisation record, 24-hour emergency contact for home-country physician PHASE 7 — LONG-TERM FOLLOW-UP (Months 6–60+): • Monthly remote follow-up via GAF Healthcare telemedicine platform for first year (tacrolimus levels, renal function, nutritional biochemistry, rejection biomarkers) • Annual in-person review at transplant centre recommended at 1 year and 3 years • Life-long immunosuppression mandatory; never self-discontinue • Stoma reversal surgery: planned at 6–12 months in stable patients • Vaccination update: all live vaccines permanently contraindicated; inactivated annual influenza, PneumoVax, and COVID-19 booster recommended
Возможные риски
Intestinal transplantation carries a higher risk profile than most other solid-organ transplants, and patients and families must receive thorough informed consent covering both early and late complications. EARLY POST-OPERATIVE RISKS (within 30 days): • Primary graft non-function or ischaemia-reperfusion injury: the intestinal graft is highly susceptible to ischaemia; severe cases may require graft enterectomy and return to TPN, with re-listing for retransplantation • Vascular thrombosis: arterial thrombosis of the SMA reconstruction (1–4%) or venous thrombosis is a surgical emergency requiring immediate re-exploration; daily Doppler ultrasound surveillance is mandatory in the first week • Acute cellular rejection (ACR): occurs in 40–60% of patients at some point in the first year; mild-to-moderate ACR is treatable with pulsed corticosteroids; severe refractory ACR may require anti-thymocyte globulin or graft removal • Antibody-mediated rejection (AMR): driven by pre-formed or de-novo donor-specific antibodies (DSA); treated with plasmapheresis, IVIG, and rituximab; carries worse graft survival outcomes than ACR • Intra-abdominal infection and anastomotic leak: the immunosuppressed, malnourished intestinal transplant recipient is at high risk; bacterial translocation from the graft itself is a unique risk in intestinal transplantation • Cytomegalovirus (CMV) enteritis: particularly severe in CMV-seronegative recipients of CMV-positive grafts (D+/R−); manifests as ulceration visible on surveillance endoscopy; treated with IV ganciclovir for minimum 3–6 weeks MEDIUM-TERM RISKS (months 1–12): • EBV-associated Post-Transplant Lymphoproliferative Disorder (PTLD): the intestinal transplant population has the highest PTLD risk of all solid-organ recipients (10–15% at 5 years), driven by EBV primary infection in a heavily immunosuppressed host; treatment requires immunosuppression reduction and rituximab; chemotherapy for aggressive cases • Chronic rejection: manifests as obliterative arteriopathy and mucosal atrophy of the allograft; leads to progressive graft dysfunction and TPN dependence; poorly responsive to treatment; the leading cause of late graft loss • Calcineurin inhibitor nephrotoxicity: up to 10–15% of intestinal transplant recipients develop chronic kidney disease requiring dose reduction, calcineurin-sparing strategies, or ultimately kidney transplant evaluation • Graft-versus-host disease (GVHD): donor immune cells engrafted in the recipient attack host tissues; manifests as skin rash, diarrhoea, liver dysfunction, and cytopenias; treated with high-dose corticosteroids and additional immunosuppression; can be life-threatening LONG-TERM RISKS (beyond 1 year): • Metabolic complications: post-transplant diabetes mellitus (tacrolimus-induced beta-cell toxicity), dyslipidaemia (sirolimus, corticosteroids), hypertension, and continued osteopaenia • De-novo malignancy: beyond PTLD, long-term immunosuppression increases the risk of skin cancers (squamous cell carcinoma) and solid organ malignancies; annual dermatology review and cancer screening are mandatory • Nutritional deficiencies: even after TPN independence, allograft absorptive capacity may be submaximal, requiring ongoing micronutrient supplementation (Vitamin D, B12, zinc, magnesium, fat-soluble vitamins) • Overall mortality context: five-year patient survival for intestinal transplant is approximately 55–65% at experienced centres — substantially improved from 35–40% in the early 2000s, but lower than kidney (85–90%) or liver (70–75%) transplantation. This reflects the immunological complexity and the severity of the underlying disease, not a deficiency of surgical technique. Patients should discuss realistic expectations comprehensively with their transplant physician.
Почему GAF Healthcare
GAF Healthcare provides comprehensive end-to-end non-medical support, recognising that the logistical demands of intestinal transplantation — which may require 5–20 months of total in-country stay — far exceed those of any other medical tourism procedure. INDIA — REGULATORY AND VISA SUPPORT: • e-Medical Visa application: GAF Healthcare prepares and submits the complete e-Medical Visa dossier for the patient plus up to two attendants (Indian e-Medical Visa allows up to three entries and an initial stay of 60 days, extendable up to 180 days). Given the prolonged nature of intestinal transplant care, our team proactively manages visa extension applications in coordination with the Foreigners Regional Registration Office (FRRO). • Mandatory NOTTO compliance: All deceased-donor transplants in India require NOTTO authorisation and state transplant coordination registry listing. GAF Healthcare's in-house regulatory team handles the documentation, foreign national registration with the respective State Organ and Tissue Transplant Organisation (SOTTO), and liaison with the hospital's transplant coordinator for real-time organ match notifications. • Transplant quota documentation: Government-regulated hospitals require proof that no suitable Indian recipient is available before an organ can be allocated to a foreign national; GAF Healthcare navigates this administrative pathway transparently. UAE — REGULATORY AND VISA SUPPORT: • UAE residents and citizens of most GCC countries do not require advance visas. Citizens of over 50 countries qualify for visa-on-arrival (30–90 days). For other nationalities, GAF Healthcare facilitates UAE medical treatment visa applications through the General Directorate of Residency and Foreigners Affairs (GDRFA), Dubai, or ADIO (Abu Dhabi Investment Office) health channels, with standard processing of 5–7 business days. • DHA and DOH approval: Transplant programmes in Dubai operate under Dubai Health Authority (DHA) oversight; those in Abu Dhabi under the Department of Health (DOH). GAF Healthcare confirms current organ transplant programme licensing status and foreign patient acceptance quotas before referral. • Extended stay support: For multi-visceral transplant patients requiring >90 days, UAE medical residency permits or long-term treatment visa extensions are coordinated through our UAE-based regulatory specialist. ACCOMMODATION AND FAMILY SUPPORT: • Long-stay serviced apartment arrangements within 5–10 minutes of the transplant centre — essential given the requirement for immediate availability on organ offer • Caregiver accommodation packages: furnished apartment or hospital guest house with kitchen access (critical for dietary compliance with transplant food safety protocols), reliable Wi-Fi for remote consultations with home-country physicians, and 24/7 security • Emergency accommodation escalation: if the patient requires unexpected readmission, the family support infrastructure remains in place without disruption CLINICAL COORDINATION AND COMMUNICATION: • Dedicated GAF Healthcare patient coordinator assigned from enquiry through repatriation — single point of contact available 7 days a week • Multilingual medical interpreters provided for Arabic, Russian, French, Swahili, Bengali, and other languages; interpreter present for all key medical consultations including informed consent discussions • Medical record translation and certification: all pre-operative foreign-language records translated to English (or the operative language of the receiving centre) by certified medical translators • Telemedicine follow-up platform: post-repatriation, patients access a structured 12-month virtual follow-up programme, with tacrolimus level reports, biopsy results, and nutritional assessments reviewed jointly by the transplant centre and the patient's home physician via GAF Healthcare's secure encrypted platform TRANSPORT AND IN-COUNTRY LOGISTICS: • Private ambulance transfer from airport to hospital on arrival (ICU-equipped for critically unwell patients arriving for urgent evaluation) • Dedicated private driver for all outpatient appointments during evaluation and post-discharge monitoring phases • Repatriation coordination: for fit-to-fly clearance, GAF Healthcare liaises with airlines for medical pre-boarding, oxygen-in-flight arrangements if required, and aeromedical escort booking (transplant-trained nurse or physician) for patients repatriating within the first 12 months post-transplant • International health insurance coordination: GAF Healthcare provides detailed cost estimates and procedure coding (ICD-10, CPT) documentation required for insurance pre-authorisation, working directly with TPA (Third Party Administrators) on the patient's behalf
Частые вопросы о процедуре «Intestine Transplant»
What is the cost of Intestine Transplant in India – Isolated & Multi-Visceral Procedures in India vs UAE?
How long do I need to stay in the country before I am fit to fly home after an Intestine Transplant?
What is the success rate of Intestine Transplant in India – Isolated & Multi-Visceral Procedures?
Как GAF Healthcare помогает выбрать лучшую больницу для «intestine transplant» в Ченнаи, Индия
Найдите лучшие больницы для «intestine transplant» в Ченнаи, Индия
На этой странице представлено 8 больниц в Ченнаи, Индия, чтобы вы могли сравнить аккредитацию и специализации в одном месте.
Поддержка, когда она нужна
Отправьте нам свои медицинские отчёты в WhatsApp или по email — наша медицинская команда изучит их и предложит больницу и план лечения.
Прозрачные, всё включено цены
Мы предоставляем единую детализированную смету, покрывающую расходы больницы и проживание — без скрытых платежей.
Организация визы, поездки и проживания
После выбора больницы мы помогаем оформить визовое приглашение, забронировать проживание рядом с больницей и организовать трансфер.
Хотите узнать примерную стоимость лечения? Используйте наш калькулятор стоимости для персональной оценки.
Частые вопросы о «Intestine Transplant» в Ченнаи, Индия
Сколько больниц направления «Трансплантация печени и гепатобилиарная хирургия» представлено в Ченнаи, Индия?
Как вы выбираете больницы для списка?
Сколько стоит лечение в Ченнаи, Индия?
Следующий шаг
Отправьте нам свои медицинские отчёты — наша команда предложит больницу и план лечения для «Intestine Transplant» в Ченнаи, Индия.
Свяжитесь с нами, если заметите неточность на этой странице.